History
A list of downloadable documents created during development.
Background information
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): EIA form for guidance development
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): final appraisal determination
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments on the appraisal consultation
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): appraisal consultation
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): appraisal consultation
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): evaluation report
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): assessment report
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): consultee and commentator comments on the assessment report
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): non-manufacturer submission
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): manufacturer full submissions
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): expert written personal statements
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): assessment report
-
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): assessment report